WorksheetsSaxenda® LeafLet
Total questions: 21
Worksheet time: 21mins
1 ml of solution of Saxenda® contains ____ mg of liraglutide. One pre-filled pen contains ____ mg of liraglutide in ____ ml solution.
Therapeutic Indications of Saxenda® in Adults:
Therapeutic Indications of Saxenda® in Adolescents:
According to the Saxenda® Leaflet :
Treatment in adults with Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least ____ of their initial body weight.
5%
4%
According to the Saxenda® Leaflet :
Treatment in adolescents with Saxenda® should be discontinued and re-evaluated if patients have not lost at least ____ of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose.
4%
5%
pH of Saxenda® :
7.15
7.5
8.15
8.5
If a dose is missed and there is less than 12 hours to the next dose, then?
The patient should take the dose as soon as possible.
The patient should not take the missed dose and resume the once-daily regimen with the next scheduled dose.
Saxenda® can be used in combination with another GLP-1 receptor agonist.
True
False
No dose adjustment is required for patients with mild or moderate renal impairment, if:
Creatinine Clearance ≥30 ml/min
Creatinine Clearance <30 ml/min
If escalation to the next dose step is not tolerated for three consecutive weeks, consider discontinuing treatment.
True
False
If pancreatitis is suspected, liraglutide should be used with caution.
True
False
In clinical trials in type 2 diabetes, thyroid adverse events, such as goitre, have been reported in particular in patients with pre-existing thyroid disease. Therefore, liraglutide should be used with caution in patients with thyroid disease.
True
False
Which of the following are Very Common adverse events of Saxenda®?
Headache
Diarrhoea
Dizziness
Dry mouth
Delayed gastric emptying*
Which of the following are Rare adverse events of Saxenda®?
Anaphylactic reaction
Acute renal failure
Renal impairment
Cholecystitis
Increased amylase
Write three Common adverse events of Saxenda®?
Liraglutide lowers body weight in humans mainly through loss of fat mass with relative reductions in visceral fat being greater than for subcutaneous fat loss.
True
False
Cmax of Liraglutide:
11 hours
12 hour
13 hours
T1/2 of Liraglutide:
11 hours
12 hour
13 hours
Liraglutide Plasma Protein binding:
>96%
>97%
>98%
>99%
Absolute bioavailability of liraglutide following subcutaneous administration is approximately:
45%
50%
55%
80%
Precautions for storage of Liraglutide after first use?
Store below 30 degree C
Store below 25 degree C
